Search Results

Kubota Vision Inc., a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced the execution of a collaboration letter of intent between Kubota Vision and AUROLAB.

Kubota Vision Inc., a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced the execution of a vendor agreement between Kubota Vision and IQVIA Services Japan G.K. for eyeMO, a portable, low-cost, home-based, remote and in-office ophthalmic OCT*1 device for monitoring of retinal diseases.

Kubota Vision Inc., a clinical-stage specialty ophthalmology company and a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced the execution of a collaborative research agreement between Kubota Vision and China Medical University Hsinchu Hospital, Department of Ophthalmology, for a study using Kubota Glass in Taiwan, led by Dr. Ying-Shan Chen.

Vanda Pharmaceuticals Inc. confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the Company for $8.00 per share in cash.

Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.

Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.

Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.